Contaminated Blood and Blood Products

David Mowat Excerpts

Thursday 14th October 2010 Commons Chamber

[David Mowat (Warrington South) (Con)]

I thank my hon. Friend the Member for Sherwood (Mr Spencer) for being brief and thereby letting me contribute to the debate, and I shall be brief as well. Like many others, I welcome the movement from the Minister over the past couple of days.

I want to make three points. I would like the Minister to comment on them in her concluding remarks, and I would certainly welcome their being addressed in her review. The first is the difference between how this problem has been dealt with in this country and other countries. A lot has been said about Ireland, but Ireland is not the only country in question: there is also Japan, Canada and Italy. It has been said that past Governments have failed to address the problem and that is true, but it is only Governments of our country who have failed. I would like to know where our response to the problem will rank in comparison with that of other countries, and I hope we will finish at least halfway up the international league table.

Secondly, I want to draw attention to the distinction we have persistently drawn between hepatitis C sufferers and HIV sufferers. When I first looked into this issue, I simply did not understand that, time and again, whenever a compensation payment was made we drew that distinction. People with hepatitis C are unable to work in the same way as those with HIV, and people with hepatitis C are also dying prematurely in the same way. We really have to stop drawing that distinction. It has even been drawn latterly in respect of the Archer report. The annual payment now being made to HIV sufferers is, I think, £12,800, whereas hepatitis C sufferers, who have about the same amount of discomfort, have merely got a review in five years’ time. That is not right.

My third point is about money, about which a number of interesting comments have been made, in particular by my hon. Friend the Member for Bracknell (Dr Lee). The cost of matching the sums we have given to the HIV folk in payments to the hepatitis C folk is 3,500 people multiplied by £12,800 a year. That comes to £40 million a year. That is the cost of implementing Archer in the same way for the hepatitis C people as for the HIV people. I would be extremely interested to hear what my Front-Bench colleague has to say about that, and I would like it to be addressed in the review. How can we reconcile that sum of £40 million a year that will not be for ever—unfortunately the number of these people is declining—with the sum of £3 billion?

Finally, let me say that this is not just about money. Had it been just about money, we would have fixed the problem 10 years ago when more money was going into the national health service than it was able to spend. This is about principle, and we have the chance to sort it out.

I also regret that the motion refers to a comparison with Ireland. That country does give eight to 10 times more money than we have been able to find, but other countries come in between ours and Ireland on that list. We should not be constrained to signing up to a one-country approach, but we have to get this fixed.